Tafinlar 50 mg (Dabrafenib (Dabrafenib Mesylate) CAPSULE) 50 MG

TAFINLAR 50 MG capsules contain dabrafenib mesylate, a medication used in cancer treatment. This oral capsule is manufactured by Novartis Pharmaceuticals Canada Inc. and is available in a 120-count pack.

Strength

50 MG

Pack Size

120

Manufacturer / TM Owner

NOVARTIS PHARMACEUTICALS CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

TAFINLAR 50 MG capsules are primarily used in the treatment of certain types of cancer. Dabrafenib mesylate, the active ingredient, is often prescribed for conditions where specific genetic mutations are present. Patients may wonder, 'What is TAFINLAR used for?' This medication is typically part of a broader cancer treatment plan, tailored to individual patient needs.

Side Effects

Common effects of TAFINLAR 50 MG capsules may include fatigue, fever, and joint pain. Some users might experience skin-related side effects such as rash or hyperkeratosis. It's important to note that individual responses to the medication can vary, and not everyone will experience these effects.

Precautions & Warnings

TAFINLAR 50 MG capsules should be handled with care and stored as directed. Patients should follow their healthcare provider's instructions regarding administration and monitoring. It's crucial to discuss any pre-existing conditions or other medications with a healthcare professional before starting TAFINLAR.

Avoid Interactions

TAFINLAR 50 MG capsules may interact with certain medications, including strong CYP3A inhibitors and inducers. Alcohol and other substances that affect liver enzymes could potentially alter the effectiveness of dabrafenib mesylate. Patients should inform their healthcare provider about all medications and supplements they are taking.

References

Frequently Asked Questions

TAFINLAR is used in the treatment of certain types of cancer, often in patients with specific genetic mutations.

TAFINLAR capsules should be taken orally, typically as prescribed by a healthcare provider.

Common side effects may include fatigue, fever, joint pain, and skin-related issues like rash or hyperkeratosis.

TAFINLAR may interact with certain medications, so it's important to discuss all current medications with a healthcare provider.

TAFINLAR can be purchased from licensed online pharmacies or through healthcare providers.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.